Document Detail


Myocardial protection by F 15845, a persistent sodium current blocker, in an ischemia-reperfusion model in the pig.
MedLine Citation:
PMID:  19778535     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
The specific persistent sodium current blocker F 15845 was tested in two myocardial ischemia-reperfusion models in the pig in order to evaluate its cardioprotective effects. In the first protocol, the left circumflex coronary artery was ligated for 60-min and then reperfused for 48-h. F 15845 (2.5+2.5 and 5+5mg/kg) was administered by i.v. infusion, starting before ischemia to the beginning of reperfusion. The second protocol attempted to evaluate F 15845 (5+5mg/kg) response in a more pathological state of the heart. To this end, a non necrotic ligation of the left circumflex coronary artery was applied for 15 min one week before the actual 60 min occlusion. For both protocols, infarct size was determined at the end of the reperfusion period and was assessed by histochemistry (tetrazolium staining). Plasma levels of biochemical markers (myoglobin and troponin I) were also evaluated. In protocol 1, F 15845 significantly reduced the infarct size by 27+/-3 and 43+/-5% at 2.5+2.5 and 5+5mg/kg, respectively. At 5+5mg/kg, F 15845 decreased plasma levels of myoglobin and cardiac troponin I. In protocol 2, F 15845 (5+5mg/kg) significantly reduced myocardial infarct size by 54+/-15% and lowered the plasma myoglobin and troponin I levels relative to vehicle-treated animals. In conclusion, the highly effective persistent sodium current blocker F 15845 exerts remarkable cardioprotective activities. It reduces both myocardial infarct size and the release of biochemical markers in healthy pigs as well in pigs previously exposed to an ischemic episode.
Authors:
Robert Létienne; Lydia Bel; Anne-Marie Bessac; Bernard Vacher; Bruno Le Grand
Related Documents :
16700825 - Cardioprotective effects of bosentan, a mixed endothelin type a and b receptor antagoni...
16382295 - Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro.
7464205 - Importance of edema and compliance changes during 24 hours of preservation of the dog h...
12602525 - Preliminary observations on the effects of acute infusion of growth hormone on coronary...
22562925 - Utilization of 3 amplatzer occluders for closure of post-myocardial infarction ventricu...
19759365 - Rapid appearance of new cerebral microbleeds after acute ischemic stroke.
Publication Detail:
Type:  Journal Article     Date:  2009-09-22
Journal Detail:
Title:  European journal of pharmacology     Volume:  624     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  16-22     Citation Subset:  IM    
Affiliation:
Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin, 81106 Castres Cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An imprinted GFP insertion reveals long-range epigenetic regulation in embryonic lineages.
Next Document:  Marrow stromal fibroblastic cell cultivation in vitro on decellularized bone marrow extracellular ma...